Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 6 (June)

1. Retrieval of autobiographical memory in Alzheimer's disease: relation to volumes of medial temporal lobe and other structures.
   Hippocampus, 15(4): 535-50. [Abstract] [Full-text]
2. The role of microglial cellular senescence in the aging and Alzheimer diseased brain.
   Rejuvenation Res, 8(2): 82-5. [Abstract] [Full-text]
3. Cognitive aging and Alzheimer's disease.
   Postgrad Med J, 81(956): 343-52. [Abstract] [Full-text]
4. CYP46: a risk factor for Alzheimer's disease or a coincidence?
   Neurosci Lett, 383(1): 105-8. [Abstract] [Full-text]
5. Expression of Ki67, PCNA and the chromosome replication licensing protein Mcm2 in glial cells of the ageing human hippocampus increases with the burden of Alzheimer-type pathology.
   Neurosci Lett, 383(1): 33-8. [Abstract] [Full-text]
6. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
   Neurosci Lett, 383(1): 12-6. [Abstract] [Full-text]
7. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.
   J Neurochem, 93(6): 1412-21. [Abstract] [Full-text]
8. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.
   J Am Geriatr Soc, 53(6): 983-90. [Abstract] [Full-text]
9. Apolipoprotein E genotype and mortality: findings from the Cache County Study.
   J Am Geriatr Soc, 53(6): 935-42. [Abstract] [Full-text]
10. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study.
    Ann Neurol, 57(6): 789-94. [Abstract] [Full-text]
11. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease.
    Ann Neurol, 57(6): 832-42. [Abstract] [Full-text]
12. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia.
    Ann Neurol, 57(6): 896-903. [Abstract] [Full-text]
13. Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease.
    J Neurosci Res, 80(6): 869-76. [Abstract] [Full-text]
14. Sex differences in the clinical manifestations of Alzheimer disease pathology.
    Arch Gen Psychiatry, 62(6): 685-91. [Abstract] [Full-text]
15. Data from a longitudinal study provided measurements of cognition to screen for Alzheimer's disease.
    J Clin Epidemiol, 58(7): 701-7. [Abstract] [Full-text]
16. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy.
    Cereb Cortex, 15(7): 995-1001. [Abstract] [Full-text]
17. Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice.
    Neuropeptides, 39(3): 233-7. [Abstract] [Full-text]
18. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med, 352(23): 2379-88. [Abstract] [Full-text]
19. Early life socioeconomic status and late life risk of Alzheimer's disease.
    Neuroepidemiology, 25(1): 8-14. [Abstract] [Full-text]
20. Longitudinal functional alterations in asymptomatic women at risk for Alzheimer's disease.
    J Neuroimaging, 15(3): 271-7. [Abstract] [Full-text]
21. Abnormal intracellular trafficking of high affinity nerve growth factor receptor, Trk, in stable transfectants expressing presenilin 1 protein.
    Brain Res Mol Brain Res, 137(1): 70-6. [Abstract] [Full-text]
22. Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease.
    Biochim Biophys Acta, 1740(3): 472-80. [Abstract] [Full-text]
23. Multidimensional measures of person knowledge and spatial associative learning: can these be applied to the differentiation of Alzheimer's disease from frontotemporal and vascular dementia?
    Neuropsychologia, 43(9): 1338-50. [Abstract] [Full-text]
24. A split-brain model of Alzheimer's disease? Behavioral evidence for comparable intra and interhemispheric decline.
    Neuropsychologia, 43(9): 1307-17. [Abstract] [Full-text]
25. Nicergoline, a drug used for age-dependent cognitive impairment, protects cultured neurons against beta-amyloid toxicity.
    Brain Res, 1047(1): 30-7. [Abstract] [Full-text]
26. Association between angiotensin-converting enzyme gene polymorphism and Alzheimer's disease in a Chinese population.
    Dement Geriatr Cogn Disord, 20(1): 52-6. [Abstract] [Full-text]
27. Evaluating associations between 5-HTTLPR polymorphism and Alzheimer's disease for Korean patients.
    Dement Geriatr Cogn Disord, 20(1): 31-4. [Abstract] [Full-text]
28. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT.
    Dement Geriatr Cogn Disord, 20(1): 25-30. [Abstract] [Full-text]
29. Do vascular lesions and related risk factors influence responsiveness to donepezil chloride in patients with Alzheimer's disease?
    Dement Geriatr Cogn Disord, 20(1): 15-24. [Abstract] [Full-text]
30. Cognitive reserve: a SPECT study of 132 Alzheimer's disease patients with an education range of 0-19 years.
    Dement Geriatr Cogn Disord, 20(1): 8-14. [Abstract] [Full-text]
31. Changes in hippocampal GABABR1 subunit expression in Alzheimer's patients: association with Braak staging.
    Acta Neuropathol (Berl), 109(5): 467-74. [Abstract] [Full-text]
32. Silver staining profiles distinguish Pick bodies from neurofibrillary tangles of Alzheimer type: comparison between Gallyas and Campbell-Switzer methods.
    Acta Neuropathol (Berl), 109(5): 483-9. [Abstract] [Full-text]
33. Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus.
    Acta Neuropathol (Berl), 109(5): 490-6. [Abstract] [Full-text]
34. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models.
    Neuropsychopharmacology, 30(6): 1111-20. [Abstract] [Full-text]
35. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Neurosignals, 14(1): 71-82. [Abstract] [Full-text]
36. Search for natural products related to regeneration of the neuronal network.
    Neurosignals, 14(1): 34-45. [Abstract] [Full-text]
37. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease.
    Neurosignals, 14(1): 6-22. [Abstract] [Full-text]
38. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Arch Neurol, 62(6): 975-80. [Abstract] [Full-text]
39. Study of plasma antioxidant status in Alzheimer's disease.
    Eur J Neurol, 12(7): 531-5. [Abstract] [Full-text]
40. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease.
    Neuroimage, 26(4): 1078-85. [Abstract] [Full-text]
41. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.
    Brain Res Brain Res Rev, 49(1): 1-21. [Abstract] [Full-text]
42. Improvement pattern in the clock drawing test in early Alzheimer's disease.
    Eur Neurol, 53(3): 140-5. [Abstract] [Full-text]
43. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment.
    Neuroimage, 26(4): 1159-63. [Abstract] [Full-text]
44. Mitochondrial DNA variants in a portuguese population of patients with Alzheimer's disease.
    Eur Neurol, 53(3): 121-4. [Abstract] [Full-text]
45. Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?
    J Neurol Neurosurg Psychiatry, 76(7): 928-33. [Abstract] [Full-text]
46. Qualitative neuropsychological performance characteristics in frontotemporal dementia and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 76(7): 920-7. [Abstract] [Full-text]
47. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
    Int J Clin Pract, 59(7): 817-22. [Abstract] [Full-text]
48. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease.
    Neurosci Lett, 384(1): 23-8. [Abstract] [Full-text]
49. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging.
    Neurosci Lett, 384(1): 183-7. [Abstract] [Full-text]
50. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.
    J Biol Chem, 280(25): 23599-604. [Abstract] [Full-text]
51. The cognitive effects of cholinesterase inhibitor treatment in every-day practice.
    Curr Med Res Opin, 21(6): 871-5. [Abstract] [Full-text]
52. Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study.
    Curr Med Res Opin, 21(5): 723-32. [Abstract] [Full-text]
53. Spiritual well-being and caregiver burden in Alzheimer's caregivers.
    Geriatr Nurs, 26(3): 154-61. [Abstract] [Full-text]
54. Microsphere embolism-induced cortical cholinergic deafferentation and impairments in attentional performance.
    Eur J Neurosci, 21(11): 3117-32. [Abstract] [Full-text]
55. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons.
    Neurosci Lett, 384(3): 288-93. [Abstract] [Full-text]
56. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Int J Geriatr Psychiatry, 20(6): 559-69. [Abstract] [Full-text]
57. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.
    Int J Geriatr Psychiatry, 20(6): 547-51. [Abstract] [Full-text]
58. A multigenerational pedigree of late-onset Alzheimer's disease implies new genetic causes.
    Brain, 128: 1707-15. [Abstract] [Full-text]
59. Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination.
    Brain, 128: 1613-21. [Abstract] [Full-text]
60. The darker side of Ca2+ signaling by neuronal Ca2+-sensor proteins: from Alzheimer's disease to cancer.
    Trends Pharmacol Sci, 26(7): 345-51. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.